A L Wan Po1. Show Affiliations » 1. Centre for Evidence-Based Pharmacotherapy, Aston University, Aston Triangle, B4 7ET, Birmingham, UK. a.liwanpo@aston.ac.uk
Abstract
Mesh： See more » AbciximabAdministration, OralAgedAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/adverse effectsAspirin/administration & dosageAspirin/adverse effectsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationDrug and Narcotic Control/legislation & jurisprudenceFemaleFibrinolytic Agents/administration & dosageFibrinolytic Agents/adverse effectsHumansImmunoglobulin Fab Fragments/administration & dosageImmunoglobulin Fab Fragments/adverse effectsInfusions, IntravenousMaleMiddle AgedMyocardial Infarction/drug therapyMyocardial Infarction/mortalityMyocardial ReperfusionPlatelet Aggregation Inhibitors/administration & dosagePlatelet Aggregation Inhibitors/adverse effectsPlatelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitorsRecombinant Proteins/administration & dosageRecombinant Proteins/adverse effectsSurvival RateThrombolytic TherapyTissue Plasminogen Activator/administration & dosageTissue Plasminogen Activator/adverse effects
Substances： See more » Antibodies, MonoclonalFibrinolytic AgentsImmunoglobulin Fab FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsreteplaseTissue Plasminogen ActivatorAspirinAbciximab
Year: 2001 PMID： 11425409 DOI： 10.1016/s0140-6736(00)05092-3
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321